Form 8-K - Current report:
SEC Accession No. 0001104659-25-059900
Filing Date
2025-06-16
Accepted
2025-06-16 16:30:51
Documents
13
Period of Report
2025-06-16
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2518123d1_8k.htm   iXBRL 8-K 24252
2 EXHIBIT 99.1 tm2518123d1_ex99-1.htm EX-99.1 16585
  Complete submission text file 0001104659-25-059900.txt   212830

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA bcli-20250616.xsd EX-101.SCH 3035
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE bcli-20250616_lab.xml EX-101.LAB 34239
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE bcli-20250616_pre.xml EX-101.PRE 22372
15 EXTRACTED XBRL INSTANCE DOCUMENT tm2518123d1_8k_htm.xml XML 3691
Mailing Address 1325 AVENUE OF AMERICAS 28TH FLOOR NEW YORK NY 10019
Business Address 1325 AVENUE OF AMERICAS 28TH FLOOR NEW YORK NY 10019 201-488-0460
BRAINSTORM CELL THERAPEUTICS INC. (Filer) CIK: 0001137883 (see all company filings)

EIN.: 207273918 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36641 | Film No.: 251050580
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)